Low mefloquine exposure has been shown to contribute to treatment failure in patients with uncomplicated falciparum malaria following a 3-day artesunate–mefloquine combination. The present study aimed to develop a population pharmacokinetic model for mefloquine based on whole blood concentration–time profiles of this target population for further dose optimization.
A total of 129 Burmese patients aged above 15 years who presented with typical symptoms of malaria and had a blood smear positive for Plasmodium falciparum were included in the study. All were treated with the standard 3-day combination regimen of artesunate and mefloquine consisting of mefloquine for 2 days and artesunate for 3 days. Blood samples were collected before and at different time points after drug administration from different sub-groups of patients. Mefloquine concentrations were quantified in whole blood using high-performance liquid chromatography. A non-linear mixed-effect modelling approach was applied for population pharmacokinetic analysis using the NONMEM v7.3 software. Covariates investigated (body weight, gender, admission parasitaemia, and molecular markers of mefloquine resistance) were investigated in a step-wise manner using the SCM functionality in Perl-Speaks-NONMEM.
Population pharmacokinetic analysis of mefloquine was performed in all patients with a total of 653 samples. Whole blood mefloquine concentration–time profiles were described by a two-compartment disposition model. Of the covariates investigated, none was found to have a significant impact on the pharmacokinetics of mefloquine. Significant differences in maximum concentration (Cmax) and elimination half-life (t1/2) were found in patients who had treatment failure (36 cases) compared to patients with successful treatment (107 cases).
The study successfully describes the pharmacokinetics of mefloquine following a 2-day treatment of mefloquine as a part of a 3-day artesunate–mefloquine in patients with uncomplicated falciparum malaria from Thailand. A model has been developed which adequately describes the pharmacokinetics of mefloquine. More extensive clinical studies including both adults and children are needed to fully characterize the pharmacokinetics of mefloquine.
WHO. World Malaria Report 2017. Geneva: World Health Organization; 2017. http://www.who.int/malaria.
WHO. World Malaria Report 2016. Geneva: World Health Organization; 2006. http://www.who.int/malaria.
WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006. http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf.
White NJ. Malaria. In: Manson’s Tropical Diseases 22 nded. Cook G, Zumla A, eds. London: Saunders; 2009.
Malaria Division of Thailand. Guideline for treatment of malaria in Thailand, 2016.
Na-Bangchang K, Muhamad P, Ruaengweerayut R, Chaijaroenkul W, Karbwang J. Identification of resistance of Plasmodium falciparum to artesunate–mefloquine combination in an area along the Thai–Myanmar border: integration of clinico-parasitological response, systemic drug exposure, and in vitro parasite sensitivity. Malar J. 2013;12:263. CrossRefPubMedPubMedCentral
WHO. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria(WHO/HTM/RBM/2003.50). Geneva: World Health Organization; 2003.
WHO. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94:1–90.
Ferreira I, do Rosário VE, Cravo P. Real-time quantitative PCR with SYBR Green I detection for estimating copy numbers of nine drug resistance candidate genes in Plasmodium falciparum. Malar J. 2006;5:71. CrossRef
Karbwang J, Molunto P, Na Bangchang K, Bunnag D. Determination of mefloquine in biological fluids using high performance liquid chromatography. Southeast Asian J Trop Med Public Health. 1989;20:55–60. PubMed
Boeckman A, Sheiner L, Beal S. NONMEM Users Guide. NONMEM Proj Group: Univ California; 2010. p. 1–61.
Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004/06/24 ed. 2004;75:85–94.
Holford N: A degenerative predictive check. In: Population approach group Europe. Pamplona; 2005.
Price RN, Nosten F, Luxemburger C, Kham A, Brockman A, Chongsuphajaisiddhi T, et al. Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg. 1992;89:523–7. CrossRef
Jullien V, Valecha N, Srivastava B, Sharma B, Kiechel J-R. Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate–mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria. Malar J. 2014;13:187. CrossRefPubMedPubMedCentral
- Population pharmacokinetics of mefloquine given as a 3-day artesunate–mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai–Myanmar border
Richard M. Hoglund
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II